These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 33583283)

  • 21. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.
    Liu X; Liu Y; Chen K; Yan S; Bai X; Li J; Liu D
    J Med Virol; 2021 Feb; 93(2):854-862. PubMed ID: 32687223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
    Kim JH; Baek YH; Lee H; Choe YJ; Shin HJ; Shin JY
    Epidemiol Health; 2021; 43():e2021004. PubMed ID: 33445824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
    Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D
    J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
    Rizk JG; Wenziger C; Tran D; Hashemi L; Moradi H; Streja E; Ahluwalia A
    Drugs; 2022 Jan; 82(1):43-54. PubMed ID: 34914085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
    Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
    Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.
    Armstrong K; Soltoff A; Rieu-Werden M; Metlay J; Haas J
    PLoS One; 2021; 16(3):e0247548. PubMed ID: 33651840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
    de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
    BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study.
    Yahyavi A; Hemmati N; Derakhshan P; Banivaheb B; Karimi Behnagh A; Tofighi R; TehraniYazdi A; Kabir A
    Intern Emerg Med; 2021 Jun; 16(4):883-893. PubMed ID: 33085063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19.
    Najafi N; Davoudi A; Izadyar H; Alishahi A; Mokhtariani A; Soleimanpourian B; Tabarrayi M; Moosazadeh M; Daftarian Z; Ahangarkani F
    Ir J Med Sci; 2023 Jun; 192(3):1517-1523. PubMed ID: 35854192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia.
    Görmez S; Erel Kırışoğlu C; Ekicibaşı ME; Değirmencioğlu A; Paudel A; Akan G; Atalar F; Sarıgüzel N; Pamukçu B
    Turk Kardiyol Dern Ars; 2021 Jun; 49(4):286-292. PubMed ID: 34106062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.
    Megaly M; Glogoza M
    Scott Med J; 2020 Nov; 65(4):123-126. PubMed ID: 32807019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study).
    Mustafic H; Fayssoil A; Josseran L; Ouadahi M; Grimaldi-Bensouda L; Dubourg O; Annane D; Mansencal N
    Am J Cardiol; 2021 May; 147():58-60. PubMed ID: 33617818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19.
    Xiang D; Ren X; Chen Q; Yu H; Li X; Liu D
    Clin Exp Hypertens; 2021 May; 43(4):305-310. PubMed ID: 33356606
    [No Abstract]   [Full Text] [Related]  

  • 36. Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients.
    Baslilar S; Saylan B
    Ann Saudi Med; 2021; 41(5):268-273. PubMed ID: 34618609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study.
    Dublin S; Walker RL; Floyd JS; Shortreed SM; Fuller S; Albertson-Junkans L; Harrington LB; Greenwood-Hickman MA; Green BB; Psaty BM
    Am J Hypertens; 2021 Apr; 34(4):339-347. PubMed ID: 33048112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy with RAS inhibitors during the COVID-19 pandemic.
    Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C
    J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.
    Chu C; Zeng S; Hasan AA; Hocher CF; Krämer BK; Hocher B
    Br J Clin Pharmacol; 2021 Jun; 87(6):2475-2492. PubMed ID: 33217033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
    Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
    PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.